Brief: Cate Clinical Trial Launched To Demonstrate The Clinical Utility Of Ctdna-Guided Treatment In Breast Cancer Using The Ultrasensitive Next Personal Test
10/09/2025 21:23
Sept 10 (Reuters) - Personalis Inc PSNL.O: CATE CLINICAL TRIAL LAUNCHED TO DEMONSTRATE THE CLINICAL UTILITY OF CTDNA-GUIDED TREATMENT IN BREAST CANCER USING THE ULTRASENSITIVE NEXT PERSONAL TEST PERSONALIS INC - PATIENTS TESTING POSITIVE TREATED WITH ELACESTRANT TO PREVENT METASTASIS Source text: ID:nBw3T8wBCa Further company coverage: PSNL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Personalis
See all newsBrief: Personalis - Announces Commercial Launch Of Real-Time Variant Tracker In Next Personal Mrd Test
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
Personalis slips as BTIG downgrades, sees no rival bid for Tempus deal
Brief: Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP
Personalis, Inc. reports results for the quarter ended June 30 - Earnings Summary